Coronavirus Vaccine Problems News ArticlesExcerpts of key news articles on coronavirus vaccine problems
In the coming months, Linda Thomas-Greenfield, President Joe Biden's ambassador to the United Nations, will hear from a growing chorus of developing nations about the foundering efforts to distribute the coronavirus vaccine globally. The nations, many of which have not even begun vaccinating their populations, are demanding that the U.S. support proposals to temporarily waive certain patent and intellectual property rights so that generic coronavirus vaccines can be produced. The proposals have been fiercely opposed by American drugmakers, including Pfizer. ASG ... represents Pfizer. Many leading figures in Biden's administration, including key White House advisers, State Department leaders, and health care officials have financial stake in or professional ties to vaccine manufacturers, which are now lobbying to prevent policies that would cut into future profits over the vaccine. ASG in particular has unusual amounts of sway in the Biden administration. State Department officials Victoria Nuland, Wendy Sherman, Uzra Zeya, and Molly Montgomery previously worked at ASG, as did Philip Gordon, Vice President Kamala Harris's national security adviser. The pharmaceutical industry, in a bid to shield an expected financial windfall, has pressed the Biden administration not only to oppose the waiver, but also to impose trade-related sanctions on countries that back [a] proposal or move to manufacture coronavirus vaccines without permission from patent holders.
A four-inch wafer of silicon has been turned into an army of one million microscopic, walking robots, thanks to some clever engineering employed by researchers at Cornell University in New York. In a paper, published Wednesday in the journal Nature, a team of roboticists detail the creation of their invisible army of robots, which are less than 0.1mm in size (about the width of a human hair) and cannot be seen with the naked eye. The robots ... take advantage of an innovative, new class of actuators, which are the legs of the microrobots. Controlling movement in these tiny machines requires the researchers to shine a laser on minuscule light-sensitive circuits on their backs, which propels their four legs forward. They've been designed to operate in all manner of environments such as extreme acidity and temperatures. One of their chief purposes, the researchers say, could be to investigate the human body from the inside. The team was able to build incredibly small legs, which are connected to two different patches on the back of the robot - one for the front pair of legs, one for the back. Alternating light between the patches propels the microrobot forward. The research team were able to show the microrobots devices could fit within the narrowest hypodermic needle and thus, could be "injected" into the body. The machines aren't intelligent enough to target a diseased cell or respond to stimuli, so there's no application for this invisible army. However, the researchers said that "their capabilities can rapidly evolve."
Note: Remember that secret military projects are often 20 years or more advanced of anything made public. Could this technology have already been developed in secret projects and used in military vaccines? Yale professor Charles Morgan describes in this two-minute video (or this one) how cells injected through hypodermic needles can cause foreign substances to be manufactured in our bodies, how they can alter a person's memory, and much more. His full presentation on psycho-neurobiology and war given at West Point Military Academy is quite disturbing.
For more than a year, the Centers for Disease Control and Prevention has collected data on hospitalizations for Covid-19 in the United States and broken it down by age, race and vaccination status. But it has not made most of the information public. When the C.D.C. published the first significant data on the effectiveness of boosters in adults younger than 65 two weeks ago, it left out the numbers for a huge portion of that population: 18- to 49-year-olds, the group least likely to benefit from extra shots, because the first two doses already left them well-protected. The agency recently debuted a dashboard of wastewater data on its website that will be updated daily and might provide early signals of an oncoming surge of Covid cases. Some states and localities had been sharing wastewater information with the agency since the start of the pandemic, but it had never before released those findings. Two full years into the pandemic, the agency leading the country's response to the public health emergency has published only a tiny fraction of the data it has collected, several people familiar with the data said. But the C.D.C. has been routinely collecting information since the Covid vaccines were first rolled out last year. The agency has been reluctant to make those figures public, [an] official said, because they might be misinterpreted as the vaccines being ineffective. Experts dismissed the potential misuse or misinterpretation of data as an acceptable reason for not releasing it.
Note: Learn also about why Pfizer wanted to hide their COVID clinical data for 75 years. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and coronavirus vaccines from reliable major media sources.
In the pages of The BMJ a decade ago, in the middle of a different pandemic, it came to light that governments around the world had spent billions stockpiling antivirals for influenza that had not been shown to reduce the risk of complications, hospital admissions, or death. The errors of the last pandemic are being repeated. Memories are short. Today, despite the global rollout of covid-19 vaccines and treatments, [the] data underlying the trials for these new products remain inaccessible to doctors, researchers, and the public–and are likely to remain that way for years to come. This is morally indefensible for all trials, but especially for those involving major public health interventions. Pfizer's pivotal covid vaccine trial was funded by the company and designed, run, analysed, and authored by Pfizer employees. The company and the contract research organisations that carried out the trial hold all the data. And Pfizer has indicated that it will not begin entertaining requests for trial data until May 2025, 24 months after the primary study completion date. The lack of access to data is consistent across vaccine manufacturers. Regulators and public health bodies could release details such as why vaccine trials were not designed to test efficacy against infection and spread of SARS-CoV-2. Had regulators insisted on this outcome, countries would have learnt sooner about the effect of vaccines on transmission and been able to plan accordingly.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Pfizer chairman Albert Bourla told NBC's Dateline host Lester Holt that the pharmaceutical company was "not certain" if the vaccine prevented the coronavirus from being transmitted, saying: "This is something that needs to be examined." In a prime-time special titled "Race for a Vaccine" ... Holt questioned Bourla and other individuals involved in the development and distribution of the vaccine. In November, Pfizer announced that its vaccine candidate had been shown to be more than 90% effective at preventing COVID-19 and has applied for emergency use authorization from the Food and Drug Administration (FDA). The U.K. became the first country to approve Pfizer's vaccine this week with the first round of immunizations expected to roll out next week. In August, Canada signed a deal with Pfizer for 20 million doses of the vaccine. In a list of interview highlights released before the special, Holt asked Bourla: "Even though I've had the protection, am I still able to transmit it to other people?" "I think this is something that needs to be examined. We are not certain about that right now with what we know," Bourla responded.
Note: An MSN article reported that a 41-year-old Portuguese health worker died two days after getting the Pfizer vaccine, but then removed the article. Learn more about this death in this article. A Florida doctor also died after receiving the vaccine. This CDC report states "December 14–23, 2020, monitoring â€¦ detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine." For more, explore the excellent, reliable resources provided in our Coronavirus Information Center.
Project Veritas released a video on Tuesday which allegedly shows an executive-level Food and Drug Administration (FDA) official admitting the Biden administration has plans to require yearly COVID shots "just like the flu shot." Christopher Cole, an executive officer for the FDA's Medical Countermeasures Initiative (MCMi), was apparently recorded on hidden camera by Project Veritas admitting "Biden wants to inoculate as many people as possible." "You'll have to get an annual shot," Cole said on camera. "I mean, it hasn't been formally announced yet 'cause they don't want to, like, rile everyone up," he added. Cole said in the video his managerial role at the FDA's MCMi involves overseeing vaccines, vaccine approvals, and devices for vaccines, and noted his "office clears all the emergency approvals" for such counter measures. "There's almost a billion dollars a year going into FDA's budget from the people we regulate," Cole says in the Project Veritas video. "The drug companies, the food companies, the vaccine companies, they pay us hundreds of millions of dollars a year to hire and keep the reviewers to approve their products. If they can get every person required at an annual vaccine, that is a recurring return of money going into their company," Cole added, in reference to pharmaceutical manufacturers. Cole also expresses concern over the FDA's process to approve COVID-19 vaccines for young children between six months of age and four years old in the video.
Note: Explore hundreds of personal stories of severe vaccine injury and death that are being strongly suppressed by government and the major media. An MD's excellent research reveals that the government knew about and actively suppressed safe, effective, low-price treatments for COVID and targeted physicians who prescribed them. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and coronavirus vaccines from reliable major media sources.
Pfizer CEO Albert Bourla on Monday said two doses of the company's vaccine may not provide strong protection against infection from the Covid omicron variant, and the original shots have also lost some of their efficacy at preventing hospitalization. Bourla, in an interview at JPMorgan's health-care conference, emphasized the importance of a third shot to boost people's protection against omicron. "The two doses, they're not enough for omicron," Bourla said. "The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations." Bourla said omicron is a more difficult target than previous variants. Omicron, which has dozens of mutations, can evade some of the protection provided by Pfizer's original two shots. Two-doses of Pfizer's or Moderna's vaccines are only about 10% effective at preventing infection from omicron 20 weeks after the second dose. A booster dose ... is up to 75% effective at preventing symptomatic infection and 88% effective at preventing hospitalization. However ... the U.K. Health Security Agency also found that boosters are only 40% to 50% effective against infection 10 weeks after receiving the shot.
Note: What happened to the 95% effectiveness touted highly in the beginning? Why weren't we told that the vaccines could lose most of their efficacy over time? Does this mean we'll need a new vaccine with every new variant? And of course, this means more billions flowing into the pockets of big Pharma. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
[During] the "swine flu affair of 1976" ... a US president decided to rush a vaccine to the entire American population based on ill-founded science and political imprudence. The mistakes that followed hold lessons for today. Lawsuits, side-effects and negative media coverage followed, and the events dented confidence in public health for years to come. It began at a US Army training base. In February 1976, several soldiers at Fort Dix fell ill with a previously unrecognised swine flu. In March, President Ford announced a $137m (Ĺ67.5m in 1976) effort to produce a vaccine by the autumn. Its goal was to immunise every man, woman and child in the US. The president himself was vaccinated on television on 14 October, further heightening perceptions that this was a politicised event. As has happened throughout the Covid-19 pandemic of 2020, the scientists could only give the best advice they could based on incomplete knowledge. As the months continued – still with no outbreak – new problems arose. Millions of vaccinations meant dozens of cases of Guillain-Barre syndrome, a rare problem where the body's immune system attacks the nerves. The swine flu strain spotted at Fort Dix was not dangerous, and there would be no pandemic. When politicians in the present day talk of "the science" as if it is a complete body of knowledge, a manual for what to do, it neglects the uncertainty of evidence and ignores that science is a human endeavour. The swine flu affair, the New York Times concluded, had been a "sorry debacle" and "fiasco" marked by political expediency and unwarranted confidence.
Note: Watch an incrediby revealing "60 Minutes" video clip on this tragic story of greed and corruption at the highest levels. Read also a Los Angeles Times article on this 1976 "debacle" where only one died from the flu while at least 25 died from the vaccine. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and vaccines from reliable major media sources.
After raking in enormous profits from its coronavirus vaccine in 2021, the U.S.-based pharmaceutical giant Pfizer has kicked off the new year by hiking the prices of more than 120 of its drugs, resulting in significantly higher costs for patients amid a deadly pandemic. That's according to a new report released Thursday by Patients for Affordable Drugs (P4AD), which found that pharmaceutical companies have raised the prices of 554 medicines this month alone. Pfizer led the way with 125 price hikes to start 2022, leading P4AD to label the company the industry's "poster child for greed." "Due to sales of its Covid-19 vaccine, which is set to be the best-selling drug of all time, Pfizer shattered profit records in 2021. Projected sales for 2022 are $54.5 billion–more than double the previous record for one-year sales for a prescription drug," the report notes. "To put this into perspective, AbbVie's Humira previously held the spot with $19.8 billion in sales, and Pfizer's best-selling product just prior to the pandemic achieved worldwide revenues of $5.8 billion." "Despite this record revenue in 2021," the report continues, "Pfizer began 2022 with price hikes on seven of its 10 best-selling drugs," including its pneumonia vaccine (up 6.9%), a breast cancer medication (up 6.9%), and a treatment for people with cardiovascular disease (up 6%). "These hikes of 5% or 6% can translate into thousands of dollars in higher costs for patients," P4AD notes.
Note: See also a Forbes article asking why physicians aren't challenging outrageous pricing for medical costs. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma profiteering from reliable major media sources.
The pharmaceutical industry keeps turning up the dial on lobbying, setting massive new spending records in its intensive effort to influence Congress and the Biden administration. Yet this week, President Biden angered drugmakers when he said he supports the waiving of intellectual property protections for coronavirus vaccines. Drug and health product manufacturers, along with their national association, spent a combined $92 million to lobby the federal government from January through March. That puts the industry on track to break its spending record for the second year in a row. Not only that, but its first-quarter spending was more than double what was spent by the second-highest-spending industry, electronics companies. There are currently 1,270 registered lobbyists for pharmaceuticals and health products – more than two lobbyists for every member of Congress. Pfizer, maker of one of the three coronavirus vaccines approved for emergency use in the United States, was the biggest spender of any individual drug company. And last year, as it was developing its vaccine, the federal government agreed to pay the company $1.95 billion for the first 100 million doses it produced. The company reported it had $3.5 billion in revenue from sales of the vaccine so far this year. Pfizer was outflanked on lobbying spending only by the Pharmaceutical Research and Manufacturers of America – the national association that represents the interests of drugmakers.
At least four candidates are near the finish line in the U.S. coronavirus vaccine race. A key point to note, however, is that the vaccine isn't an end-all solution to the pandemic. That's in large part because any inoculations developed now are focused on simply preventing symptoms from arising, rather than blocking out the virus altogether. The latter goal is a secondary endpoint, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. "The primary thing you want to do is that if people get infected, prevent them from getting sick, and if you prevent them from getting sick, you will ultimately prevent them from getting seriously ill," Fauci said. "What I would settle for, and all of my colleagues would settle for, is the primary endpoint to prevent clinically recognizable disease," he said. That level of protection would be the ultimate goal to diffusing the crisis, but is hard to do with companies facing an immediate demand for some sort of solution. While no vaccine is 100% effective, having a majority of the population inoculated and higher percentages of efficacy is the best to hope for. The U.K. is looking at challenge trials, which intentionally infect a smaller group of participants with the virus in an effort to test a vaccine's or treatment's efficacy. Fauci said the U.S. is not anticipating such a move because the rate of spread is so high in the country that it's sufficient enough of an environment to test the vaccine.
Note: This Bloomberg article further shows the vaccines are not designed to stop the virus. Why is the media not doing a better job of informing the public about this. Read also this CNBC article titled "Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccine issues from reliable major media sources.
Moderna, Pfizer, AstraZeneca, and Johnson & Johnson are leading candidates for the completion of a Covid-19 vaccine likely to be released in the coming months. These companies have published their vaccine trial protocols. Close inspection of the protocols raises surprising concerns. These trials seem designed to prove their vaccines work, even if the measured effects are minimal. Prevention of infection is not a criterion for success for any of these vaccines. In fact, their endpoints all require confirmed infections and all those they will include in the analysis for success, the only difference being the severity of symptoms between the vaccinated and unvaccinated. Measuring differences amongst only those infected by SARS-CoV-2 underscores the implicit conclusion that the vaccines are not expected to prevent infection, only modify symptoms of those infected. We all expect an effective vaccine to prevent serious illness if infected. Three of the vaccine protocols - Moderna, Pfizer, and AstraZeneca - do not require that their vaccine prevent serious disease only that they prevent moderate symptoms which may be as mild as cough, or headache. A vaccine must significantly or entirely reduce deaths from Covid-19. None list mortality as a critical endpoint.
Note: Read also this article in BMJ (British Medical Journal) titled "Will covid-19 vaccines save lives? Current trials aren't designed to tell us." And this CNBC article is titled "Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccine issues from reliable major media sources.
Some 85 percent of Portugal's population is fully vaccinated. Portugal's feat has turned the country into a cutting-edge pandemic laboratory – a place where otherwise-hypothetical questions about the coronavirus endgame can begin to play out. Chief among them is how fully a nation can bring the virus under control when vaccination rates are about as high as they can go. Portugal's experience is ... providing a note of caution: a reminder that 1˝ years into this pandemic, the current tools of science still might not be enough. Herd immunity remains elusive. "We have achieved a good result, but it's not the solution or miracle one would think," Portugal's health minister, Marta Temido, said in an interview. In Portugal, seniors are vaccinated at a level verging on the statistically impossible: Official data puts the rate at 100 percent. But many were also vaccinated more than half a year ago – and studies from around the world, from the United States to Israel, have warned of a drop in protection by that point. One of the biggest warnings of all has come from a science institute in Lisbon, where researchers have been measuring antibody levels in several thousand people – including about 500 in Portuguese nursing homes. Shortly after those nursing home residents were vaccinated, all with the vaccine from Pfizer-BioNTech, 95 percent developed antibodies, the researchers found. But this summer ... more than one-third of the residents had lost antibodies entirely.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Israel has among the world's highest levels of vaccination for COVID-19, with 78% of those 12 and older fully vaccinated. Yet the country is now logging one of the world's highest infection rates, with nearly 650 new cases daily per million people. More than half are in fully vaccinated people. The effects of waning immunity may be beginning to show. A preprint published last month by physician Tal Patalon and colleagues ... found that protection from COVID-19 infection during June and July dropped in proportion to the length of time since an individual was vaccinated. People vaccinated in January had a 2.26 times greater risk for a breakthrough infection than those vaccinated in April. At the same time, cases in the country, which were scarcely registering at the start of summer, have been doubling every week to 10 days since then, with the Delta variant responsible for most of them. What is clear is that "breakthrough" cases are not the rare events the term implies. As of 15 August, 514 Israelis were hospitalized with severe or critical COVID-19, a 31% increase from just 4 days earlier. Of the 514, 59% were fully vaccinated. To try to tame the surge, Israel has turned to booster shots. As of Monday, nearly 1 million Israelis had received a third dose. Yet boosters are unlikely to tame a Delta surge on their own, says Dvir Aran, a biomedical data scientist at Technion. Aran's message for the United States and other wealthier nations considering boosters is stark: "Do not think that the boosters are the solution."
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Sen. Rand Paul (R-KY) has been heavily criticized by those on the Left for fighting back against mask and vaccine mandates. He was censored by Big Tech and vilified by Democratic politicians. Consider the recent admission by Dr. Deborah Birx regarding the efficacy of the COVID-19 vaccines. Birx, the former White House COVID response coordinator, stated in an interview with Neil Cavuto on Fox News that she knew the vaccines wouldn't stop infections. Birx's comments align with what Paul was saying last year regarding the vaccines and the sycophantic nature in which Democrats were pushing them on the public. "I knew these vaccines were not going to protect against infection," Birx said. "I think we overplayed the vaccines, and it made people then worry that it's not going to protect against severe disease and hospitalization. It will. But let's be very clear: 50% of the people who died from the omicron surge were older, vaccinated." Consider Paul's comments in an exchange with Department of Health and Human Services Secretary Xavier Becerra last September. Paul challenged Becerra on the efficacy of vaccines compared to natural immunity. At the time, Paul was one of only a few people who challenged those in charge. Some even claimed Paul's words were causing people to die. As it turns out, Paul was right, and they were wrong. "The science is against you on this. The science is clear. Naturally acquired immunity is as good as a vaccine," Paul said.
Note: Watch the revealing interview where Dr. Birx makes these comments. Note that Birx is promoting Paxlovid for which the gov't pays $530 per person and is offering free of charge. So who do you think pays for this ultimately? And who profits? The official narrative on COVID is falling apart as shown in the evidence in this great article. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
A federal judge in Texas on Thursday ordered the Food and Drug Administration to make public the data it relied on to license Pfizer's COVID-19 vaccine, imposing a dramatically accelerated schedule that should result in the release of all information within about eight months. That's roughly 75 years and four months faster than the FDA said it could take to complete a Freedom of Information Act request by a group of doctors and scientists seeking an estimated 450,000 pages of material about the vaccine. The court "concludes that this FOIA request is of paramount public importance," wrote U.S. District Judge Mark Pittman. The FDA didn't dispute it had an obligation to make the information public but argued that its short-staffed FOIA office only had the bandwidth to review and release 500 pages a month. While Pittman recognized "the 'unduly burdensome' challenges that this FOIA request may present to the FDA," in his four-page order, he resoundingly rejected the agency's suggested schedule. Rather than producing 500 pages a month – the FDA's proposed timeline – he ordered the agency to turn over 55,000 a month. That means all the Pfizer vaccine data should be public by the end of the summer rather than, say, the year 2097. Aaron Siri of Siri & Glimstad, who represents the plaintiffs, in an email said the decision "came down on the side of transparency and accountability." His clients ... have pledged to publish all the information they receive from the FDA on their website.
Note: Why did almost no major media pick up this important article? And read this revealing article on 800 individuals who Pfizer reported withdrew from their vaccine studies, some because of health problems which could have been caused by the vaccine. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Longtime vaccine critic Robert F. Kennedy Jr. has a runaway bestseller on his hands with his blockbuster book skewering Dr. Anthony Fauci, no thanks to what his publisher calls a "total media blackout." "The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health" continued its reign Wednesday atop the Amazon and USA Today nonfiction bestseller lists and ranked fifth on The New York Times' list of top-selling books. The book is flying off the shelves even though technology platforms refuse to carry its advertising. Mainstream media outlets won't touch it, much to the frustration of Tony Lyons, president and publisher of Skyhorse Publishing. "I defy you to find a single case where the No. 1 bestselling book in America over a 16-day period has not been mentioned in one mainstream newspaper in the country," Mr. Lyons [said]. Not even the aura of the Kennedy name has tempted the mainstream media. The snub hasn't occurred in a vacuum. Mr. Kennedy became persona non grata after he launched his vaccine criticism in 2005. Dr. Fauci is a media favorite, and social media companies have cracked down on content that contests the coronavirus authorities in the name of squelching "misinformation." Among the book's claims are that the White House chief medical adviser oversaw the "disastrous mismanagement" of the 2020 pandemic and has prioritized the pharmaceutical industry over public health.
Note: If you don't have time for the whole book (rated 4.9 stars on amazon.com), you can find an engaging summary of key points on this webpage. Learn how the CIA is involved in suppressing Kennedy's book and so much more. For more along these lines, see concise summaries of deeply revealing news articles on media manipulation and the coronavirus from reliable sources.
The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine's apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results. The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses. Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca's data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger. The fact that the initial half-strength dose wasn't tested in older participants, who are especially vulnerable to Covid-19, could undermine AstraZeneca's case to regulators that the vaccine should be authorized for emergency use.
Note: Learn in this revealing article how vaccine trials are rigged. This article spells out how vaccine makers are above the law and face no consequences for damage from vaccines. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.
Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.
On 28 July 2021, Pfizer and BioNTech posted updated results for their ongoing phase 3 covid-19 vaccine trial. The preprint came almost a year to the day after the historical trial commenced, and nearly four months since the companies announced vaccine efficacy estimates "up to six months.". But you won't find 10 month follow-up data here. While the preprint is new, the results it contains aren't particularly up to date. Since late last year, we've heard that Pfizer and Moderna's vaccines are "95% effective." Measuring vaccine efficacy two months after dosing says little about just how long vaccine-induced immunity will last. "Waning immunity" is a known problem for influenza vaccines, with some studies showing near zero effectiveness after just three months. And so the recent reports from Israel's Ministry of Health caught my eye. In early July, they reported that efficacy against infection and symptomatic disease "fell to 64%." By late July it had fallen to 39% where Delta is the dominant strain. This is very low. For context, the FDA's expectation is of "at least 50%" efficacy for any approvable vaccine. Now Israel, which almost exclusively used Pfizer vaccine, has begun administering a third "booster" dose to all adults over 40. The US plans to follow suit. Until new clinical trials demonstrate that boosters increase efficacy above 50%, without increasing serious adverse events, it is unclear whether the 2-dose series would even meet the FDA's approval standard at six or nine months.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.